Biotechnology

Friday Jan 22, 2021 - 12:50 pm

InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes Registered Direct Offering for $2.2 Million, Announces $4.1 Million Registered Direct Offering

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed on its previously announced registered direct offering; the company also announced that it has completed definitive agreements with a number of institutional and accredited investors for a registered direct offering. According to the announcement, POAI’s previously announced offering closed with 2,200,000…

Thursday Jan 21, 2021 - 11:40 am

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Announces Plans to Develop Micro Brain E-Tattoo Device for Growing Brain Diagnostics Market

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has begun development of a brain E-Tattoo device. The company announced that the innovative product will feature a temporary implanted or imprinted minimally invasive, subcutaneous graphene electrode paired with a micro EEG. The electrodes will connect to the micro EEG, which will be located behind the ear and which processes signals from the sensors and…

Thursday Jan 21, 2021 - 11:00 am

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Beginning of MS1819 Extension Study with Initial Dosing of Two Patients

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, has begun its Phase 2b OPTION 2 extension study of MS1819. AZRX announced that the first two patients have been dosed in the extension study of MS1819, which uses immediate release capsules for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. MS1819 is…

Thursday Jan 21, 2021 - 10:29 am

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Slated to Present Trailblazing Gene Therapies at the MoneyShow Accredited Investors Virtual Expo

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, this morning announced that the company’s President and Chief Executive Officer, Rodney Varner, will provide a company overview at the MoneyShow Accredited Investors Virtual Expo taking place virtually January 26-28, 2021. GNPX’s presentation will shine a light on recent advancements concerning its upcoming clinical trials for the…

Wednesday Jan 20, 2021 - 10:47 am

InvestorNewsBreaks — MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Announces Lab Test Results of Patented Biopesticide Achieve 100% Control of Root-Rot Disease

MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural science-based biological solutions for high-value crops, has announced successful test results of its patented mustard-derived biopesticide on Aphanomyces euteiches zoospores ("Aphanomyces"). The tests, conducted via an independent third-party facility, achieved 100% control of the root-rot disease Aphanomyces zoospores at economic application rates within 24 hours; Aphanomyces is a soil-borne disease that destroys…

Wednesday Jan 20, 2021 - 10:46 am

InvestorNewsBreaks – Pressure BioSciences Inc. (PBIO) Announces Collaboration to Evaluate Feasibility of Ultra Shear Technology Platform to Improve Effectiveness of SinuSys Lead Product Candidate

Pressure BioSciences (OTCQB: PBIO), today announced a collaboration with SinuSys Corporation aimed at evauating the potential for PBI's innovative Ultra Shear Technology(TM) ("UST") platform to strengthen the effectiveness of SinuSys Corp's lead product candidate Restora. Depending on the outcome of the collaboration, SinuSys plans to license PBI's UST platform for use with Restora on its path to FDA approval in a phase IIb clinical study later…

Wednesday Jan 20, 2021 - 10:23 am

InvestorNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Hires IR Firm Torrey Hills Capital

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced its engagement of Rancho Santa Fe, California-based investor relations firm San Diego Torrey Hills Capital, Inc. ("Torrey Hills Capital") to deliver market awareness and investor relations services to IMEXF, subject to acceptance by the Canadian Securities Exchange ("CSE").…

Wednesday Jan 20, 2021 - 9:38 am

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Strategy for New Year; Outlines Expected Milestones

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has released its business strategy and expected milestones for 2021. The company noted that in the coming year it anticipates commercialization of its proprietary rapid COVID-19 PCR (“PCR”) test as well as clinical validation of is exclusive transdermal and sublingual drug formulations; XPhyto is also planning on…

Wednesday Jan 20, 2021 - 9:14 am

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Executive Chairman Quoted in Elite Healthcare Article Noting How the Pandemic Might Impact Healthcare in 2021

Brain Scientific (OTCQB: BRSF) co-founder and executive chairman Boris Goldstein was quoted in a recent Elite Healthcare article titled “A Look at 2021 Healthcare with the Pandemic.” The article quoted a variety of clinicians and industry professionals who consider themselves futurists and who specialize in exploring predictions and possibilities based on present trends. The article discussed health care in 2021 from a variety of standpoints including…

Tuesday Jan 19, 2021 - 11:13 am

InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announced Definitive Agreements for $2.2 Million Registered Direct Offering

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has entered into definitive agreements for the issuance and sale of more than 2 million shares of its common stock. The company announced that it has finalized definitive agreements with a number of institutional and accredited investors for the issuance and sale of approximately 2,200,000 common…

Tuesday Jan 19, 2021 - 10:33 am

InvestorNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Verifies Active Ingredient in Biopesticide Offering Positively Impacts Soil Health

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural biological protection for high value crops, this morning reported that third party studies have confirmed that Allyl Isothiocyanate ("AITC"), the active ingredient in MustGrow's mustard plant-based technology, has a positive impact on soil health, contributing to the environmental and ecological security of plant-based food supply and the planet. The company’s…

Friday Jan 15, 2021 - 9:48 am

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Featured in Pharma Mirror Magazine Article

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, was featured in a recent article published by Pharma Mirror Magazine. The article titled, “Neurology’s Growing Need for Disposable Technologies,” is written by Brain Scientific’s co-founder and executive chairman. The piece indicates that several studies have recently shown that the development of neurological conditions and symptoms are prevalent in COVID patients. “When conditions like…

Thursday Jan 14, 2021 - 1:00 pm

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Slated to Present at NobleCon17

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has announced that it will present at the upcoming NobleCon17, scheduled for Jan. 19–20, 2021. The virtual event is Noble Capital Markets’ annual investor conference. GNPX’s presentation will include a company overview and address the company’s recent progress on planned clinical trials focusing on the treatment of…

Thursday Jan 14, 2021 - 11:58 am

InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Subsidiary Sells Media to Top Research Medical Centers

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that TumorGenesis, POAI’s wholly owned subsidiary, sold media to top research medical centers in New York City and Boston. The announcement noted that those two sales are repeat orders and focus on culturing ovarian cancer cells with specific research goals; the company also announced…

Thursday Jan 14, 2021 - 11:19 am

InvestorNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Confirms Proceeds of C$1.5M from Warrant Exercise

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural biological protection for high value crops, today announced its receipt of over C$1.5 million from the exercise of approximately 3.2 million common share purchase warrants at an average weighted exercise price of C$0.48 per share. The company intends to use the proceeds of the warrant exercise to advance its organic…

Wednesday Jan 13, 2021 - 11:27 am

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Passes Final Release Tests for Manufacturing Run of Proprietary Immunogene Therapy Treatment

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, announced that it has achieved a significant milestone for its REQORSA(TM) Immunogene Therapy. The company has met all specifications and passed all final release tests for its initial scaled-up, clinical-grade manufacturing run of REQORSA(TM) immunogene therapy. This achievement comes in advance of GNPX’s upcoming Acclaim-1 and Acclaim-2…

Wednesday Jan 13, 2021 - 11:24 am

InvestorNewsBreaks – LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) Initiates Program to Identify UK, South African COVID Sequences

LexaGene Holdings (TSXV: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced that it has started a series of studies required by the FDA for Emergency Use Authorization (“EUA”) testing for its COVID-19 assay in a point-of-care (“POC”) environment using its fully automated MiQLab(TM) system. “I’m excited we have progressed to the point where we have started…

Wednesday Jan 13, 2021 - 11:02 am

InvestorNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTC: IMEXF) Engages IBN, Builds Momentum for 2021

Imagin Medical (CSE: IME) (OTC: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced it has selected the corporate communications expertise of the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. Under the partnership, IBN will leverage its investor-based distribution network of 5,000+ key syndication outlets,…

Wednesday Jan 13, 2021 - 10:32 am

InvestorNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Appoints Diabetes, Behavioral Health Experts to Scientific Advisory Board

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced the appointment of two renowned experts to its Scientific Advisory Board (“SAB”). Dr. Marilyn Ritholz, psychologist at Joslin Diabetes Center, a Harvard Medical School affiliate, and Dr. David Horwitz, former global chief medical officer of Johnson & Johnson Diabetes Institute, join SAB chairman Eric Milledge; the prestigious board is focused on advancing Dario's…

Wednesday Jan 13, 2021 - 9:46 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Appears on C3 Chat Show Podcast

CNS Pharmaceuticals (NASDAQ: CNSP) chairman and CEO John Climaco was featured on a recent C3 Chat Show Podcast. The podcast, hosted by Sid Vaidya and Eric Gershey, explores topics related to entrepreneurship, life experiences and best practices. During his interview, Climaco shared the history of CNS Pharmaceuticals and provided an update on the company’s recent business progress, including the fact that the company recently received FDA…

Tuesday Jan 12, 2021 - 12:57 pm

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Focuses on Multi-Omic Approach to Personalized Treatment Options

Predictive Oncology (NASDAQ: POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. The company is building a business around an emerging approach to disease prevention and treatment that identifies the variability in genes, environment and lifestyle for each individual, and then uses that information to provide individualized treatments designed to ultimately improve patient…

Tuesday Jan 12, 2021 - 11:47 am

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX), First Wave, Receive Notice of Allowance for Niclosamide Patent

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, announced that it, along with First Wave Bio Inc., has received a notice of allowance from the United States Patent and Trademark Office (“USPTO”). The notice of allowance is for issuance of a patent that covers use of niclosamide as a treatment for COVID-19-associated GI disease.…

Monday Jan 11, 2021 - 1:23 pm

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at H.C. Wainwright BIOCONNECT 2021

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced that management will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference. According to the update, the presentation is now available for on-demand listening by visiting https://ibn.fm/OVOdD. In addition, the press release can also be viewed on the…

Monday Jan 11, 2021 - 12:10 pm

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at the Biotech Showcase(TM) Digital 2021 Conference

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it will present at the Biotech Showcase(TM) Digital 2021 Conference. According to the update, the conference is taking place online between January 11-15 and will feature prerecorded sessions of…

Friday Jan 08, 2021 - 12:22 pm

InvestorNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) COO Shines the Spotlight on Proprietary Tech, Unique Value Proposition

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an innovative agriculture biotech company focused on providing natural biological protection for high value crops, was featured in a recent SmallCap-Investor interview. The company’s COO Colin Bletsky joined the interview to discuss MustGrow and its unique value proposition and ambitious plans for the future. Bletsky explained that a rigorous scientific process stands behind MustGrow’s proprietary technology, in which…

Friday Jan 08, 2021 - 12:19 pm

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces $3M Registered Direct Offering

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 3,650,840 shares of its common stock at a purchase price of $0.842 per share. The company expects to secure gross proceeds of…

Friday Jan 08, 2021 - 11:56 am

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Issues Letter to Shareholders

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today issued a letter to its shareholders and the investment community from its CEO and President James Sapirstein. The letter discusses AzurRx BioPharma’s optimism and enthusiasm for 2021 and its extraordinary accomplishments in the face of so many recent challenges. “This year, already, we are building on the…

Thursday Jan 07, 2021 - 12:28 pm

InvestorNewsBreaks – Atara Biotherapeutics Inc. (NASDAQ: ATRA) Secures $175M in Underwritten Public Offering

Atara Biotherapeutics (NASDAQ: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, has closed an underwritten public offering of 5,102,041 shares of its common stock at the public offering price of $24.50 per share. According to the update, pre-funded warrants of 2,040,816 shares…

Thursday Jan 07, 2021 - 11:08 am

InvestorNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Announces New VP of Broker and Consultant Partnerships

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has appointed Claudia Rimerman Kraut in the newly created role of vice president of broker and consultant partnerships. Kraut comes to her new responsibilities with impressive senior-management experience at Omada Health, American Well, AIG, United Healthcare and Humana. Kraut will lead Dario's benefit consultant and alliance outreach and be a senior member of DRIO’s employer…

Thursday Jan 07, 2021 - 10:45 am

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Participation in Biotech Showcase Digital 2021 Conference

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, will be participating in the upcoming Biotech Showcase Digital 2021 conference. The multiday event is scheduled for Jan. 11–15, 2021. As part of the company’s planned participation, AzurRx president and CEO James Sapirstein, along with other members of the senior management team, will attend virtual one-on-one meetings with registered investors and pharmaceutical…

Thursday Jan 07, 2021 - 10:14 am

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Releases Disposable Pediatric EEG Headset

Earlier this month, Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, announced that its proprietary NeuroCap(TM) would be available for pediatric patients in the United States. The company noted that the child-sized EEG headset reduces the time typically needed to measure and mark a pediatric patient’s head, as well as for post-test sanitation protocols; the company also observed that the pediatric-sized NeuroCap, designed…

Wednesday Jan 06, 2021 - 12:22 pm

InvestorNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics Completes QM CoRE(TM) Integration

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its wholly owned subsidiary Helomics has completed the integration of Quantitative Medicine’s (“QM”) novel active-learning Computational Research Engine (CoRE(TM)). According to the update, CoRE was integrated with Helomics’ proprietary TumorSpace(TM) knowledgebase of 150,000 tumor drug response profiles and the TruTumor(TM) patient primary tumor…

Wednesday Jan 06, 2021 - 10:50 am

InvestorNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) Announces Participation in Two Upcoming Virtual Events

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, will be presenting at two investor conferences in January: the SNN Network Canada Virtual Event and the H.C. Wainwright Bioconnect 2021 Virtual Conference. Company founder and CEO Dr. Jack Regan will represent LexaGene at both events. The SNN Network Canada Virtual Event is scheduled for Thursday, Jan. 7,…

Wednesday Jan 06, 2021 - 10:44 am

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) to Participate in H.C. Wainwright BioConnect Virtual Conference

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced that it will participate in the virtual H.C. Wainwright BioConnect Conference taking place on Jan. 11-14, 2021. According to the update, AzurRx BioPharma president and CEO James Sapirstein will take part in virtual one-on-one meetings with registered investors and pharmaceutical companies. Sapirstein will be available to…

Wednesday Jan 06, 2021 - 9:31 am

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at Upcoming H.C. Wainwright Bioconnect Conference

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, on Tuesday announced that it will present at the H.C. Wainwright Bioconnect 2021 Conference. According to the update, the presentation will be available on-demand throughout the event from Jan. 11-14, 2021, starting…

Wednesday Jan 06, 2021 - 8:30 am

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Launches Proprietary Technology for Obstructive Sleep Apnea Treatment

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including obstructive sleep apnea, announced its commercial launch of AireO2(TM). AireO2 is a new patient-management software technology designed to assist health-care providers to diagnose, treat and monitor patients with obstructive sleep apnea (“OSA”) and its related conditions. With an estimated 1 billion people suffering…

Tuesday Jan 05, 2021 - 2:03 pm

InvestorNewsBreaks – United Medical Equipment Business Solutions Network Inc.’s App Assists with Well-Informed Decisions

United Medical Equipment (“UME”) has created a powerful app designed for health-care professionals, caregivers, students and family members who are providing direct and indirect patient care and education. Providing critical information and access to real-time tools, UME’s Medication Management app features more than a dozen different functionalities. The app enables access to a library for up-to-date information on medications and their indications, dosage, side effects,…

Tuesday Jan 05, 2021 - 12:42 pm

InvestorNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Featured in Equity Research Report

INmune Bio (NASDAQ: INMB), a biotechnology company focused on modulating components of the innate immune system to treat cancers and chronic neurological diseases, was featured in an equity research report by Quantum Media Group LLC. Quantum announced its coverage initiative on INmune Bio on Dec. 30, 2020, and provided details on its research paper that discusses the paradigm shift in Alzheimer’s research and treatment strategies…

Monday Jan 04, 2021 - 2:35 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Shares Objectives for Berubicin Phase 2 Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently hosted a webinar to discuss the clinical design for its upcoming Phase 2 trial. The trial will study its lead drug candidate, Berubicin, for the treatment of glioblastoma multiforme (“GBM”), an aggressive form of brain cancer currently considered…

Monday Jan 04, 2021 - 2:02 pm

InvestorNewsBreaks – Retractable Technologies Inc. (NYSE: RVP) Named ‘2020’s Stock of the Year’ by The Bowser Report

Retractable (NYSE: RVP), a manufacturer and marketer of safety syringes and other innovative medical products for the health care industry, was recognized as the “Stock of the Year” for 2020 by The Bowser Report LLC. The report reads, “Unlike last year’s top pick [Repro Med Systems Inc. (NASDAQ: KRMD)], Retractable Technologies is a recent addition to the newsletter, named Company of the Month in January…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions